高危高血压患者择期腹部大手术中高 vs 标准血压目标:HISTAP 多中心随机临床试验
HISTAP 为意大利 18 个中心的多中心随机试验,纳入≥60 岁、需家庭治疗的慢性高血压、择期腹部大手术且至少一项额外高危标准的患者,术中平均动脉压目标分为≥80 mmHg(治疗组)或≥65 mmHg(对照组)。630 例完成试验并纳入意向性分析,中位年龄 74 岁。主要复合终点(术后死亡和至少一项主要器官功能障碍)治疗组 38.1% vs 对照组 48.9%(相对风险 0.78;95%CI 0.65-0.93;P=0.006)。急性肾损伤治疗组 23.5% vs 对照组 33.7%(P=0.005)。
要点
- 在高危高血压患者择期腹部大手术中,术中平均动脉压目标≥80 mmHg 较≥65 mmHg 降低主要复合终点(38.1% vs 48.9%;RR 0.78;95%CI 0.65-0.93;P=0.006)。
- 急性肾损伤治疗组 23.5% vs 对照组 33.7%(P=0.005),减少的主要是轻中度急性肾损伤。
- 治疗组术中平均动脉压 88±9 mmHg,对照组 77±7 mmHg。
- 该结果来自接受持续血流动力学监测和方案化液体治疗的增加术后风险人群。
适用人群与场景
- 年龄≥60 岁、患有慢性高血压需要家庭治疗、接受择期腹部大手术、且至少有一项额外高危标准的患者。
- 研究在意大利 18 个中心进行,患者接受持续血流动力学监测和方案化液体治疗。
处置流程与药物剂量
- 术中平均动脉压目标:治疗组≥80 mmHg,对照组≥65 mmHg。
研究设计与关键结果
- HISTAP 为多中心随机试验,在意大利 18 个中心于 2023 年 3 月至 2025 年 4 月进行,共随机 636 例,排除 6 例因随机后手术取消,630 例完成试验并纳入意向性分析(中位年龄 74 岁,IQR 69-79)。
- 术中平均动脉压:对照组 77±7 mmHg,治疗组 88±9 mmHg。
- 主要复合终点(术后死亡和至少一项主要器官功能障碍)治疗组 38.1% vs 对照组 48.9%(相对风险 0.78;95%CI 0.65-0.93;P=0.006)。
- 急性肾损伤治疗组 23.5% vs 对照组 33.7%(P=0.005),治疗组显著更少。
证据类型、等级与局限
- 证据类型:多中心随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于接受持续血流动力学监测和方案化液体治疗、术后风险增加的高血压患者行择期腹部大手术时,术中平均动脉压目标≥80 mmHg 较≥65 mmHg 可减少主要器官功能障碍,主要由于轻中度急性肾损伤减少。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: The optimal mean arterial pressure (MAP) target in high-risk hypertensive patients undergoing major abdominal surgery remains unclear. The HISTAP trial evaluated whether targeting an intraoperative MAP ≥ 80 compared with ≥ 65 mmHg reduces postoperative organ dysfunction and 30-day mortality, in this population.
METHODS: HISTAP was a multicenter, randomized trial conducted at 18 Italian centers between March 2023 and April 2025. The study included patients aged ≥ 60 years with chronic hypertension requiring home therapy, undergoing elective major abdominal surgery and having at least one additional high-risk criterion. The intraoperative MAP was targeted to ≥ 80 mmHg (Treatment group) or ≥ 65 mmHg (Control group). The primary outcome was a composite endpoint including postoperative mortality and at least one major organ dysfunction.
FINDINGS: Of 636 randomized patients, 6 were excluded since surgery was canceled after randomization, 630 completed the trial and were included in the intention-to-treat analysis (median age, 74 years [IQR, 69-79]). Mean intraoperative MAP was 77 ± 7 mmHg in the Control group and 88 ± 9 mmHg in the Treatment group. The primary composite outcome occurred in 48.9% of patients in the Control group versus 38.1% of patients in the Treatment group (relative risk, 0.78; 95% CI 0.65-0.93; P = 0.006). Acute kidney injury was significantly less frequent in the Treatment group (23.5 vs. 33.7%; P = 0.005).
INTERPRETATION: Among hypertensive patients receiving continuous hemodynamic monitoring and protocolized fluid therapy at increased postoperative risk undergoing major abdominal surgery, targeting an intraoperative MAP ≥ 80 mmHg, compared with ≥ 65 mmHg, reduced major organ dysfunction, primarily due to fewer mild-to-moderate acute kidney injuries.
TRIAL REGISTRATION: The HISTAP trial has been registered at ClinicalTrials.gov, NCT05637606 (Date of registration: 24 November 2022).
参考来源
- Cecconi M, Cortegiani A, Noto A, et al. HIgh versus STAndard blood Pressure target in hypertensive high-risk patients undergoing elective major abdominal surgery: the HISTAP multicenter randomized clinical trial. Intensive Care Med. 2026. PMID: 42370999. doi:10.1007/s00134-026-08501-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。